Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.66 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 18/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103712 | 0.89 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL104346 | 0.84 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659309 | 0.82 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658983 | 0.80 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL3996861 | 0.80 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658733 | 0.79 | GABRA1 (0.64) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2658463 | 0.78 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL3996859 | 0.78 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL5775431 | 0.78 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL3997628 | 0.78 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | GABRA1 762/4885GABRG2 779/4885GABRB3 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.